000411.SHE Zhejiang Int'L Group Co Ltd
- Market cap
- CNY 5.51B
- P/E
- 11.3x
- P/B
- 1.04x
- ROE
- 7.4%
- Dividend yield
- 5.98%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000411.SHE undervalued?
Graham number000411.SHE trades 27.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Int'L Group Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Int'L Group Co Ltd yet.
Zhejiang Int'L Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Int'L Group Co Ltd
Zhejiang Int'l Group Co.,Ltd. engages in the wholesale and retail of pharmaceuticals and medical devices in China. It offers chemical drugs, biological products, and traditional Chinese medicine. The company was founded in 1950 and is headquartered in Hangzhou, China.
Full company profileZhejiang Int'L Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Int'L Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 17.3B | 18.9B | 20.5B | 24.6B | 25.0B | 26.7B | 30.6B | 32.1B | 33.4B | 33.7B | 34.6B |
| Gross Profit | 974M | 1.14B | 1.35B | 1.64B | 1.55B | 1.74B | 1.97B | 2.19B | 2.30B | 2.36B | 2.37B |
| Operating Income | 259M | 273M | 306M | 467M | 468M | 559M | 644M | 826M | 839M | 999M | 799M |
| EBITDA | 420M | 466M | 534M | 724M | 682M | 777M | 862M | 1.04B | 1.03B | 1.19B | 762M |
| Net Income | 86.8M | 83.5M | 93.9M | 151M | 157M | 168M | 212M | 489M | 526M | 501M | 400M |
| EPS | 0.35 | 0.33 | 0.38 | 0.55 | 0.53 | 0.53 | 0.65 | 1.03 | 0.96 | 0.93 | 0.71 |
| Balance Sheet | |||||||||||
| Total Assets | 6.99B | 9.08B | 8.99B | 10.8B | 11.3B | 12.2B | 13.2B | 13.9B | 14.6B | 16.8B | 18.4B |
| Total Liabilities | 5.29B | 7.18B | 6.91B | 7.80B | 8.04B | 8.73B | 9.28B | 9.13B | 9.42B | 11.0B | 12.3B |
| Shareholders' Equity | 759M | 843M | 930M | 1.52B | 1.66B | 1.90B | 2.08B | 4.25B | 4.64B | 5.10B | 5.42B |
| Cash & Short-term Investments | 801M | 1.62B | 1.56B | 1.57B | 1.82B | 1.90B | 865M | 1.61B | 1.59B | 1.94B | 1.42B |
| Total Debt | 822M | 2.30B | 2.34B | 2.29B | 2.61B | 2.74B | 1.98B | 2.54B | 2.36B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 142M | 158M | 166M | 221M | 332M | 326M | 391M | 425M | 410M | 356M | - |
| Capital Expenditure | 93.5M | 89.6M | 114M | 137M | 178M | 189M | 107M | 168M | 280M | 237M | 305M |
| Free Cash Flow | 48.0M | 68.9M | 52.4M | 83.5M | 154M | 137M | 284M | 257M | 130M | 119M | -1.87B |
| Ratios | |||||||||||
| ROE | 11.4% | 9.9% | 10.1% | 10.0% | 9.4% | 8.9% | 10.2% | 11.5% | 11.3% | 9.8% | 7.4% |
| ROA | 1.2% | 0.9% | 1.0% | 1.4% | 1.4% | 1.4% | 1.6% | 3.5% | 3.6% | 3.0% | 2.2% |
| Net Profit Margin | 0.5% | 0.4% | 0.5% | 0.6% | 0.6% | 0.6% | 0.7% | 1.5% | 1.6% | 1.5% | 1.2% |
| Debt to Equity | 1.08x | 2.73x | 2.51x | 1.51x | 1.57x | 1.45x | 0.95x | 0.60x | 0.51x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Int'L Group Co Ltd dividends
- Dividend yield
- 5.98%
- Forward dividend
- 0.35 CNY
- Payout ratio
- 65.8%
- Ex-dividend date
- Jul 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 330M | 0.61 | 65.8% |
| 2024 | CNY 295M | 0.54 | 56.2% |
| 2023 | CNY 209M | 0.44 | 42.8% |
| 2022 | CNY 51.1M | 0.16 | 24.0% |
| 2021 | CNY 16.2M | 0.05 | 9.6% |
| 2020 | CNY 15.2M | 0.05 | 9.7% |
| 2019 | CNY 27.0M | 0.10 | 17.8% |
| 2018 | CNY 129M | 0.52 | 138.0% |
| 2017 | CNY 131M | 0.52 | 157.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 17, 2022.
Who owns Zhejiang Int'L Group Co Ltd
- Insiders 70.14%
- Institutions 0.39%
- Public & others 29.47%
- Shares outstanding 565M
- Free float 173M
Zhejiang Int'L Group Co Ltd company profile
- Company name
- Zhejiang Int'L Group Co Ltd
- Ticker
- 000411.SHE
- ISIN
- CNE0000008D9
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jun 26, 1996
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3,603
- Fiscal year end
- December
- Address
- No. 198 Zhenchuang Lane, Hangzhou, China, 310015
- Phone
- 86 571 8602 2582
- Website
- intmedic.com
About Zhejiang Int'L Group Co Ltd
Zhejiang Int'l Group Co.,Ltd. engages in the wholesale and retail of pharmaceuticals and medical devices in China. It offers chemical drugs, biological products, and traditional Chinese medicine. The company was founded in 1950 and is headquartered in Hangzhou, China.
Zhejiang Int'L Group Co Ltd management
7- Ms. Yang WangGM & Chairman · born 1981
- Mr. Dezhi CaoDeputy GM & Financial Director · born 1986
- Ms. Min Ying WuDeputy General Manager & Director · born 1976
- Ms. Qiong LiuDeputy GM & Director · born 1973
- Mr. Jiang TanSecretary of the Board of Directors · born 1985
- Mr. Ke XuDeputy General Manager · born 1985
- Kang YuAccounting Supervisor